Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Vaccination
100%
Lymphoma
100%
B-cell Lymphoma
100%
Multiple Myeloma
100%
Idiotype
100%
Vaccination Strategy
100%
Immune Response
80%
Myeloma
60%
Clinical Benefit
40%
Clinical Outcomes
20%
Immune System
20%
Tumor
20%
T Cell Activation
20%
Immunoglobulin
20%
Tumor Antigen
20%
Lymphoma Patients
20%
Progression-free Survival
20%
Clinical Response
20%
Clinical Efficacy
20%
Phase I Study
20%
Therapeutic Vaccine
20%
Antigen Presentation
20%
Idiotype Vaccine
20%
Phase II Trial
20%
Phase I Trial
20%
Antigen Delivery
20%
Vaccine Target
20%
Tumor Eradication
20%
Medicine and Dentistry
B-Cell Lymphoma
100%
Multiple Myeloma
100%
Immunoglobulin Idiotype
100%
Immune Response
50%
Myeloma
50%
Neoplasm
16%
Clinical Trial
16%
Tumor Antigen
16%
T Cell
16%
Cell Function
16%
Antigen
16%
Progression Free Survival
16%
Tumor
16%
Therapeutic Vaccine
16%
Immune System
16%
Phase III Trials
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
B Cell Lymphoma
100%
Immunoglobulin Idiotype
100%
Vaccination
100%
Myeloma
50%
Clinical Trial
16%
Neoplasm
16%
Tumor Antigen
16%
Progression Free Survival
16%
Antigen
16%
Therapeutic Vaccine
16%
Phase III Trials
16%
Immunology and Microbiology
B Cell
100%
Multiple Myeloma
100%
Idiotype
100%
Immune Response
50%
Antigen
16%
Cell Function
16%
T Cell
16%
Tumor Antigen
16%
Progression Free Survival
16%
Immune System
16%